  To assess the speed of relief provided by flurbiprofen 8.75 mg spray and lozenge and their effect on many of the different qualities and characteristics of throat<symptom> pain<symptom> and discomfort , and the many articulations of the broad term `` sore<symptom> throat<symptom> '' ( ST). Four hundred and forty adults with recent-onset , moderate-to-severe ST due to upper respiratory<disease> tract<disease> infection<disease> ( URTI) were randomized to a single dose of either flurbiprofen 8.75 mg spray ( n = 218) or flurbiprofen 8.75 mg lozenge ( n = 222). Throat<symptom> swabs for bacterial culture were taken at baseline. ST relief was assessed at 1 minute , 1 and 2 hours post-dose using the Sore<symptom><symptom> Throat<symptom> Relief Rating Scale. The change from baseline at 1 and 2 hours post-dose in difficulty swallowing and swollen throat<symptom> was assessed using the difficulty swallowing scale and the swollen throat<symptom> scale , respectively. Patients ' experience of URTI symptoms was assessed using a URTI questionnaire at baseline and 2 hours post-dose. The change in Qualities of Sore<symptom><symptom> Throat<symptom> Index , a 10-item index of qualities of ST , from baseline at 2 hours post-dose was also measured. ST relief was evident in the spray and the lozenge treatment groups at 1 minute , 1 and 2 hours post-dose ( Non-inferiority was established , and flurbiprofen spray and lozenge provided effective relief from ST pain and many of the other commonly reported qualities of ST.